Erratum: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer (British Journal of Cancer (2013) 109 (416-421) DOI: 10.1038/bjc.2013.332);Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

British Journal of Cancer

Volumn 109, Issue 2, 2013, Pages 416-421

  Stotz, M ^a   Gerger, A ^a   Eisner, F ^a   Szkandera, J ^a   Loibner, H ^b   L Ress, A ^a   Kornprat, P ^a   A Zoughbi, W ^a   Seggewies, F S ^a   Lackner, C ^a   Stojakovic, T ^a   Samonigg, H ^a   Hoefler, G ^a   Pichler, M ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Apeiron Biologics Forschungs und Entwicklungsgesellschaft MbH   (Austria)

Author keywords

inflammation; pancreatic cancer; prognosis

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MODIFIED GLASGOW PROGNOSTIC SCORE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; PANCREAS ADENOCARCINOMA; PLATE COUNT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR MICROENVIRONMENT;

EID: 84881115045     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.591     Document Type: Erratum

References (31)

1. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A (2008) Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18(1): 3-10.
2. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE, Moons KG (2003) External validation is necessary in prediction research: A clinical example. J Clin Epidemiol 56(9): 826-832.
3. Buyukkaya E, Karakas MF, Karakas E, Akcay AB, Kurt M, Tanboga IH, Sen N (2012) Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost.
4. Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW (2007) Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 9(6): 456-460.
5. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917): 860-867.
6. David M, Lepage C, Jouve JL, Jooste V, Chauvenet M, Faivre J, Bouvier AM (2009) Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 101(2): 215-218.
7. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14(7): 1766-1773.
8. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP (2011) Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 35(4): 868-872.
9. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S (2012) Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med 5(1): 2.
10. Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, Imrie CW, Carter R, McKay CJ, McMillan DC (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 18(8): 2318-2328.
11. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, Hezel A, El-Bardeesy N, Bronson RT, Sugarbaker D, Maser RS, Shapiro SD, Wong KK (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene 25(14): 2105-2112.
12. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, Kim YJ (2011) Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 104(5): 504-510.
13. Mallappa S, Sinha A, Gupta S, Chadwick S (2013) Preoperative neutrophil lymphocyte ratio greater than five is a prognostic factor for recurrent colorectal cancer. Colorectal Dis 15(3): 323-328.
14. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203): 436-444.
15. Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, Merchant N, Johnson CS, Lillemoe KD, Grutzmann R (2009) Pancreatic acinar cell carcinoma: A multi-institutional study. J Gastrointest Surg 13(8): 1495-1502.
16. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108(4): 901-907.
17. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, Ulfman LH, Leenen LP, Pickkers P, Koenderman L (2012) A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 122(1): 327-336.
18. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, Rahman SH (2009) Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 35(6): 605-610.
19. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow Inflammation Outcome Study. Br J Cancer 104(4): 726-734.
20. Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1): 149-163.
21. Sanjay P, de Figueiredo RS, Leaver H, Ogston S, Kulli C, Polignano FM, Tait IS (2012) Preoperative serum C-reactive protein levels and postoperative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP 13(2): 199-204.
22. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY (2008) Acinar cell carcinoma of the pancreas in the United States: Prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg 12(12): 2078-2086.
23. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M (2011) Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 17(7): 867-897.
24. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
25. Sun C, Ansari D, Andersson R, Wu DQ (2012) Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 18(35): 4944-4958.
26. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45(11): 1950-1958.
27. Terradas R, Grau S, Blanch J, Riu M, Saballs P, Castells X, Horcajada JP, Knobel H (2012) Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: A retrospective cohort study. PloS One 7(8): E42860.
28. Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, Rabl H, Uggowitzer M, Jilek K, Leitner G, Bauernhofer T (2013) Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol; e-pub ahead of print 27 February 2013.
29. Tsai JC, Sheu SH, Chiu HC, Chung FM, Chang DM, Chen MP, Shin SJ, Lee YJ (2007) Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 23(2): 111-118.
30. Tummala P, Junaidi O, Agarwal B (2011) Imaging of pancreatic cancer: An overview. J Gastrointest Oncol 2(3): 168-174.
31. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH (2012) Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 29(5): 3092-3100.